Get the Stockscreener App
56.26
2.46%
-1.42
After Hours:
55.79
-0.47
-0.84%
Crispr Therapeutics Ag stock is traded at $56.26, with a volume of 3.25M.
It is down -2.46% in the last 24 hours and up +15.67% over the past month.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
See More
Previous Close:
$57.68
Open:
$56.221
24h Volume:
3.25M
Relative Volume:
1.09
Market Cap:
$4.86B
Revenue:
$170.10M
Net Income/Loss:
$-239.59M
P/E Ratio:
-20.09
EPS:
-2.8
Net Cash Flow:
$-191.20M
1W Performance:
-14.83%
1M Performance:
+15.67%
6M Performance:
+35.27%
1Y Performance:
-1.80%
1-Day Range:
$56.00
$58.50
1-Week Range:
$56.00
$67.37
52-Week Range:
$30.04
$71.13
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Name
Crispr Therapeutics Ag
Sector
Industry
Phone
(617) 315-4600
Address
BAARERSTRASSE 14, ZUG
Compare CRSP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
56.26 | 4.98B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-14-25 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-12-25 | Upgrade | TD Cowen | Sell → Hold |
| Feb-03-25 | Initiated | H.C. Wainwright | Buy |
| Aug-06-24 | Reiterated | Needham | Buy |
| Aug-02-24 | Initiated | Rodman & Renshaw | Buy |
| Jun-28-24 | Resumed | Guggenheim | Neutral |
| Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
| Dec-11-23 | Downgrade | TD Cowen | Market Perform → Underperform |
| Oct-17-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Sep-27-23 | Initiated | Mizuho | Buy |
| Aug-17-23 | Upgrade | Citigroup | Neutral → Buy |
| May-30-23 | Initiated | William Blair | Outperform |
| Apr-13-23 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Mar-17-23 | Initiated | Bryan Garnier | Buy |
| Mar-07-23 | Initiated | Robert W. Baird | Neutral |
| Oct-11-22 | Initiated | Morgan Stanley | Underweight |
| Aug-09-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Jun-23-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Oct-19-21 | Initiated | SVB Leerink | Outperform |
| Jun-14-21 | Upgrade | Citigroup | Sell → Neutral |
| Apr-21-21 | Upgrade | Jefferies | Hold → Buy |
| Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
| Dec-10-20 | Reiterated | Chardan Capital Markets | Buy |
| Dec-10-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-10-20 | Reiterated | Needham | Buy |
| Dec-07-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Oct-05-20 | Initiated | BofA Securities | Buy |
| Jul-28-20 | Reiterated | Needham | Buy |
| Jul-14-20 | Initiated | SunTrust | Buy |
| Jun-15-20 | Reiterated | Canaccord Genuity | Buy |
| Mar-05-20 | Initiated | Stifel | Hold |
| Feb-03-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-19-19 | Upgrade | William Blair | Mkt Perform → Outperform |
| Nov-12-19 | Upgrade | Oppenheimer | Perform → Outperform |
| Aug-01-19 | Initiated | Jefferies | Buy |
| Jul-26-19 | Initiated | Canaccord Genuity | Buy |
| Jun-10-19 | Initiated | ROTH Capital | Buy |
| Apr-12-19 | Initiated | Evercore ISI | Outperform |
| Mar-14-19 | Initiated | William Blair | Mkt Perform |
| Jan-28-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-22-19 | Downgrade | Citigroup | Neutral → Sell |
View All
Crispr Therapeutics Ag Stock (CRSP) Latest News
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know - sharewise.com
How volatile is CRISPR Therapeutics AG stock compared to the marketAI Powered Review For 2025 - jammulinksnews.com
Is CRISPR Therapeutics AG stock overvalued or undervaluedStock Strategy Signals For Smart Trading - jammulinksnews.com
Published on: 2025-07-30 00:12:31 - beatles.ru
CRISPR Therapeutics (NASDAQ:CRSP) Trading Down 4.1%Should You Sell? - MarketBeat
Should You Invest in CRISPR Therapeutics (CRSP) Based on Bullish Wall Street Views? - Yahoo Finance
CRISPR Therapeutics AG (NASDAQ:CRSP) is ARK Investment Management LLC's 10th Largest Position - MarketBeat
CRISPR Therapeutics AG (CRSP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release - MSN
Nikko Asset Management Americas Inc. Reduces Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Buy Signal for CRISPR Therapeutics AG Stock Key Technical Indicators to WatchFast Return Equity Trade Forecast Points to Small Caps - metal.it
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Purchased by Envestnet Asset Management Inc. - MarketBeat
Cerity Partners LLC Acquires Shares of 6,351 CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG Breakout Confirmed by Volume MetricsDaily Growth Stock Pick Reports Show Bullish Signals - metal.it
13,475 Shares in CRISPR Therapeutics AG (NASDAQ:CRSP) Purchased by Inspire Advisors LLC - MarketBeat
Cathie Wood Offloads $16.4M of CRISPR Therapeutics Stock, Adds Absci and Iridium - AInvest
CRISPR Therapeutics to Report Q2 Earnings: What's in the Cards? - Yahoo Finance
How does CRISPR Therapeutics AG compare to its industry peersGet expert advice on portfolio optimization - jammulinksnews.com
What are the technical indicators suggesting about CRISPR Therapeutics AGConsistent double returns - jammulinksnews.com
The 3 Things That Matter for Vertex Pharmaceuticals Now - The Motley Fool
What are analysts’ price targets for CRISPR Therapeutics AG in the next 12 monthsLightning-fast growth - jammulinksnews.com
What makes CRISPR Therapeutics AG stock price move sharplyDaily Trade Opportunity - Metal.it
CRISPR Therapeutics (NASDAQ:CRSP) Price Target Lowered to $78.00 at Bank of America - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by Private Advisor Group LLC - MarketBeat
Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics - Benzinga
Jim Cramer Weighed in on These 17 Stocks - Insider Monkey
CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know - MSN
What drives CRISPR Therapeutics AG stock priceExceptional stock performance - PrintWeekIndia
CRISPR Therapeutics (NASDAQ:CRSP) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Is CRISPR Therapeutics AG a good long term investmentDynamic growth stocks - PrintWeekIndia
CRISPR Therapeutics AG Stock Analysis and ForecastExplosive portfolio gains - Autocar Professional
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade - MSN
[Latest] Global CRISPR Gene Editing Market Size/Share Worth - GlobeNewswire
[Latest] Global CRISPR Gene Editing Market Size/Share Worth USD 12.6 Billion by 2034 at a 13.01% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - Yahoo Finance
CRISPR Therapeutics Bets On Gene Editing’s Future With Casgevy - Finimize
CRISPR Therapeutics (CRSP) Surges 71% Last Quarter With Inclusion In Russell Indices - simplywall.st
Crispr Therapeutics: Shares Are SoaringThis Could Be The Start Of Something Big (CRSP) - Seeking Alpha
Crispr Therapeutics AG (CRSP) Receives a Buy from Bank of America Securities - The Globe and Mail
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know - MSN
What analysts say about CRISPR Therapeutics AG stockTremendous gains - jammulinksnews.com
Crispr Therapeutics Ag Stock (CRSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.43%
2.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):